Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

JPMorgan Chase & Co. (JPM): Why You Should Buy This Bank Amid Negative Sector Outlook

Page 1 of 2

On the face of it, JPMorgan Chase & Co. (NYSE:JPM) is a risky investment. Not only is it trading intimately close to its 52-week high of $55.90, but it is also on the center stage of a possible industry-wide pullback. Incertitude has shrouded the banking sector following the Fed’s announcement on impending cutbacks to economic aid. A 2011 audit of the Federal Reserve reveals that economic aid, which was instituted post-2008 to correct the negative implications of the financial crisis, totaled $16 trillion at the time. As of now, this figure is set to have increased and Fed Chairman Ben Bernanke believes that it’s high time the government pulled out and let the economy run itself.

JPMorgan Chase & Co (NYSE:JPM)

If the Fed-driven fears hold, an investor exodus will most definitely hit the banking sector. Does this mean that you should join the crowd? No it doesn’t. If you embrace a long-term buy-and-hold strategy, this is the time to establish a position in, or add more of JPMorgan to your portfolio. Despite trading close to its 52-week high, JPMorgan Chase & Co. (NYSE:JPM)’s prospects in little-discussed areas suggest that it could soon break its banks and venture into an entirely new share price territory.

Housing rebound presents alternative growth path

Behind the doomsday headlines surrounding the banking sector, interesting developments are happening. While it’s not news that the housing sector is rebounding, a good number of people seem to be oblivious to the rate at which it is rebounding and, further still, the implications that this uptrend will have on banks.

The National Association of Realtors offers that existing home sales in May hit highs not seen since 2009, increasing 12.9% year-on-year. This remarkable improvement was also accompanied by overall improvement in other key metrics in the housing sector.

The banking sector has gained immensely from the ripple effect of the housing rebound. JPMorgan Chase & Co. (NYSE:JPM)’s competitor Bank of America Corp (NYSE:BAC), which is incidentally trying to regain its market share in the mortgage market, underwrote $24 billion in home loans for the first three months of the year. This, however, waned in comparison to JPMorgan, which originated $53 billion in mortgages during the same period.

As far as the housing rebound goes, Bank of America is creating a prime leeway for its competitors. The bank has been pulled into a loan modification lawsuit. The lawsuit involves the bank’s former employees and a group of homeowners who allege that their requests for loan modifications under the Federal Home Affordable Modification Program were turned down, for the most part fraudulently. The testimonies under the case are outrageous. Former bank employees offer that they were under orders from above to lie through their teeth to unsuspecting clients.

While Citigroup Inc (NYSE:C) and JPMorgan Chase & Co. (NYSE:JPM) were found to have failed on at least 12 benchmarks instituted to assess banks’ progress on settlements, they accepted their mistakes and vowed to make amends. Bank of America Corp (NYSE:BAC), however, remains mum–even in the face of the ongoing legal brawl. While this may have a negative effect on Bank of America’s public image, it is on the flipside a key opportunity for JPMorgan to gnaw into Bank of America Corp (NYSE:BAC)’s mortgage market; especially now that the housing sector is rebounding.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!